Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
- 1 April 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 14 (4) , 378-390
- https://doi.org/10.1634/theoncologist.2008-0261
Abstract
Learning Objectives: Evaluate the mechanism of action of vandetanib in the care of patients with thyroid cancer. Analyze the current status of clinical development and early clinical results observed with vandetanib. Determine appropriate dose and schedule of administration, safety, and identification of molecular biomarkers predictive of response.This article is available for continuing medical education credit at CME.TheOncologist.com.Keywords
This publication has 54 references indexed in Scilit:
- RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancerExpert Review of Anticancer Therapy, 2008
- Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor modelAnti-Cancer Drugs, 2007
- A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145Investigational New Drugs, 2006
- Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted TherapyClinical Cancer Research, 2006
- Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerJournal of Cellular Physiology, 2005
- ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With RadiotherapyClinical Cancer Research, 2004
- The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinomaAngiogenesis, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- The Hallmarks of CancerCell, 2000